These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38532478)

  • 21. Evaluation and learning in complex, rapidly changing health systems: China's management of health sector reform.
    Xiao Y; Husain L; Bloom G
    Global Health; 2018 Nov; 14(1):112. PubMed ID: 30454037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe.
    Årdal C; Lacotte Y; Ploy MC
    Clin Infect Dis; 2020 Nov; 71(8):1994-1999. PubMed ID: 32060511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Probing popular and political discourse on antimicrobial resistance in China.
    Yu AY; Rogers Van Katwyk S; Hoffman SJ
    Glob Health Res Policy; 2019; 4():6. PubMed ID: 30859138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19's Impact on China's Strategic Emerging Industries: An Observation of Policy Difficulties.
    Li D; Dai W; Guan W
    Front Public Health; 2021; 9():778548. PubMed ID: 35059378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: the past, present, and future.
    Ohashi T; Nagashima M; Kawai N; Ohmagari N; Tateda K
    Expert Rev Anti Infect Ther; 2022 Dec; 20(12):1603-1614. PubMed ID: 36368311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Policy experimentation and innovation as a response to complexity in China's management of health reforms.
    Husain L
    Global Health; 2017 Aug; 13(1):54. PubMed ID: 28774319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global analysis of strategies to tackle antimicrobial resistance.
    Adeniji F
    Int J Pharm Pract; 2018 Feb; 26(1):85-89. PubMed ID: 28544416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance.
    Årdal C; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2017 Oct; 65(8):1378-1382. PubMed ID: 29017240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Research on wind power industrial policies' functional mechanism to the quality of enterprise innovation.
    Wang X; Tao Z; Pan G; Zou H; Xie Y; Li X
    Environ Sci Pollut Res Int; 2023 Mar; 30(12):34350-34362. PubMed ID: 36509957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of and microbial resistance to antibiotics in China: a path to reducing antimicrobial resistance.
    Cui D; Liu X; Hawkey P; Li H; Wang Q; Mao Z; Sun J
    J Int Med Res; 2017 Dec; 45(6):1768-1778. PubMed ID: 29239248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Government policy interventions to reduce human antimicrobial use: protocol for a systematic review and meta-analysis.
    Rogers Van Katwyk S; Grimshaw JM; Mendelson M; Taljaard M; Hoffman SJ
    Syst Rev; 2017 Dec; 6(1):256. PubMed ID: 29237496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study on the impact of R&D input intensity on technological innovation output - Based on data from China's high technology industry.
    Jin C; Li D
    PLoS One; 2023; 18(10):e0292851. PubMed ID: 37847711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regional technology gap and innovation efficiency trap in Chinese pharmaceutical manufacturing industry.
    Lai H; Shi H; Zhou Y
    PLoS One; 2020; 15(5):e0233093. PubMed ID: 32433705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Balancing medical innovation and affordability in the new healthcare ecosystem in China: Review of pharmaceutical pricing and reimbursement policies.
    Chen V; Shao W
    Health Care Sci; 2023 Dec; 2(6):381-391. PubMed ID: 38938625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tracking the current rise of chinese pharmaceutical bionanotechnology.
    Lenoir T; Herron P
    J Biomed Discov Collab; 2009 Oct; 4():8. PubMed ID: 19838996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can China's industrial policies enhance the green competitiveness of the manufacturing industry?
    Zhao Q; Yuan CH
    PLoS One; 2021; 16(6):e0253774. PubMed ID: 34191838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Systematic Government-Driven Green Development Transformation Strategy with Chinese Characteristics: The Case Study of the Xining Metropolitan Area.
    Xu J; Yang Y; Jia Z; Chang G; Zhang Y; Zhao M; Wang W
    Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repairing the broken market for antibiotic innovation.
    Outterson K; Powers JH; Daniel GW; McClellan MB
    Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Policy text analysis of antimicrobial resistance governance in China: A focus on national-level policies.
    Tang Y; Chen X; Liu C; Xue T; Li Y; Gao J
    Int J Antimicrob Agents; 2024 Sep; 64(3):107286. PubMed ID: 39084572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Policy actors and human and animal health practitioners' perceptions of antimicrobial use and resistance in Tanzania: A qualitative study.
    Frumence G; Mboera LEG; Katale BZ; Sindato C; Kimera S; Durrance-Bagale A; Mshana SE; Clark TG; Rweyemamu MM; Legido-Quigley H; Matee M
    J Glob Antimicrob Resist; 2021 Jun; 25():40-47. PubMed ID: 33662643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.